Verseon

Research to be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Verseon’s anti coagulants are as effective as NOACS at preventing arterial and venous thromboembolism and thrombin-induced pulmonary embolism. Lead candidate has low renal clearance compared to NOACS - highly desirable for patients with impaired renal function. - November 30, 2016